Kairos Pharma Ltd. (KAPA)
$1.52
+0.11
(+7.8%)▲
Market is closed - opens 7 PM, 15 Oct 2024
Performance
- $1.48$1.64$1.52
2.63%
Downside
Day's Volatility :9.76%
Upside
7.32%
- $1.22$4.00$1.52
19.74%
Downside
52 Weeks Volatility :69.5%
Upside
62.0%
Returns
| Period | Kairos Pharma Ltd. | Index (Russel 2000) |
|---|---|---|
3 Months | -45.77% | 0.0% |
6 Months | -45.77% | 0.0% |
1 Year | -45.77% | 0.0% |
3 Years | -45.77% | -22.2% |
Highlights
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Kairos Pharma Ltd. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kairos Pharma Ltd. | -45.77% | -45.77% | -45.77% | -45.77% | -45.77% |
 Regeneron Pharmaceuticals, Inc. | -11.92% | 13.03% | 20.39% | 82.8% | 232.53% |
 Novo Nordisk A/s | -12.32% | -3.12% | 18.68% | 139.03% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 5.16% | 92.5% | 70.0% | 35.85% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -1.58% | 21.23% | 28.8% | 164.82% | 177.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kairos Pharma Ltd. | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Regeneron Pharmaceuticals, Inc. | 26.88 | 26.88 | 1.38 | 45.01 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.8 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kairos Pharma Ltd. | NA | NA | -45.77% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.1B | 232.53% | 26.88 | 32.04% |
Novo Nordisk A/s | Buy | $523.9B | 361.43% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $124.3B | 177.5% | 32.84 | -4.74% |
Company Information
Organization | Kairos Pharma Ltd. |
Industry | Miscellaneous |
Discover More
Orion Energy Systems Inc
$1.52
+7.8%
Innovator Intl Developed Power Buffer Etf - June
$1.52
+7.8%
Bny Mellon Concentrated Intl
$1.52
+7.8%
Fidelity International Multifactor Etf
$1.52
+7.8%
Innovator Us Equity Accelerated Plus Etf - April
$1.52
+7.8%
Amplify Seymour Cannabis Etf
$1.52
+7.8%
Ebang International Holdings Inc
$1.52
+7.8%
Yieldmax Ai Option Income Strategy Etf
$1.52
+7.8%
First Trust Ultra Short Duration Municipal Etf
$1.52
+7.8%